Giovanni Barosi

TL;DR: This research presents a novel and scalable approach to personalized medicine that aims to provide real-time information about the prognosis of myelofibrosis in patients with a history of central giant cell granuloma.

TL;DR: The data on hemopoietic stem cell transplantation with reduced-intensity conditioning in myelofibrosis with myeloid metaplasia are encouraging, and an accurate risk stratification is a pivotal procedure for selecting patients who will receive the greatest benefit for transplantation.

TL;DR: The outcome of young people with myelofibrosis is unpredictable, but a normal level of hemoglobin and the absence of blast cells and constitutional symptoms at presentation identifies subjects with a low probability of rapid disease progression.

TL;DR: It is suggested that rHuEPO can be effective in correcting long‐lasting anaemia after marrow transplantation, characterized by inadequate erythropoietin production.

TL;DR: It is suggested that MF patients with thrombocytopenia experience greater symptomatic burden than MF patients without thromBocy topenia and may benefit from additional therapies.